XNCR Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

12.600

Open

12.600

VWAP

12.30

Vol

490.00K

Mkt Cap

902.80M

Low

11.980

Amount

6.03M

EV/EBITDA(TTM)

Total Shares

73.34M

484.35M

EV/OCF(TTM)

P/S(TTM)

7.35

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Events Timeline

(ET)

2026-03-24

16:20:00

Major Averages Close Lower as Oil Surges Above $90

2026-03-24

12:00:00

Dow Jones Up 0.31% to 46,350.65 Points

2026-03-09 (ET)

2026-03-09

16:10:00

Xencor Terminates Collaboration Agreement with Genentech

2026-03-08 (ET)

2026-03-08

22:30:00

KKR Plans to Sell CoolIT Systems for Over $3B

2026-03-08

17:00:00

Dr. Vinay Prasad to Leave Agency at End of April

2026-03-04 (ET)

2026-03-04

16:10:00

Xencor Expects Cash to Reach $380M to $400M by 2026

News

4.5

03-24NASDAQ.COM

US Stocks Decline Amid Ongoing Iran Conflict

4.5

03-24NASDAQ.COM

US Stocks Decline Amid Ongoing Iran Conflict

4.5

03-24NASDAQ.COM

US Stocks Decline Amid Ongoing Iran Conflict

9.5

03-05seekingalpha

Xencor Lowers Outlook After Royalty Dispute

9.5

03-05Benzinga

Xencor Lowers Revenue Outlook for Ultomiris Royalties

9.5

02-25seekingalpha

Xencor Q4 Earnings Beat Expectations Despite Revenue Decline

5 Analyst Rating

Wall Street analysts forecast XNCR stock price to rise

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

20.00

Averages

26.25

High

30.00

Current: 0.000

Low

20.00

Averages

26.25

High

30.00

JPMorgan

Overweight -> Neutral

downgrade

$18 -> $13

AI Analysis

2026-03-24

Reason

JPMorgan

Price Target

$18 -> $13

AI Analysis

2026-03-24

downgrade

Overweight -> Neutral

Reason

JPMorgan downgraded Xencor to Neutral from Overweight with a price target of $13, down from $18. The firm views the company's 2026 as an "execution year." Xencor's pipeline will need time to develop, the analyst tells investors in a research note.

JPMorgan

Overweight

Neutral

downgrade

$18 -> $13

2026-03-24

Reason

JPMorgan

Price Target

$18 -> $13

2026-03-24

downgrade

Overweight

Neutral

Reason

JPMorgan downgraded Xencor to Neutral from Overweight with a price target of $13, down from $18. The firm sees 2026 as more of a clinical execution year for Xencor. XmAb819's first clear cell renal cell carcinoma data were "encouraging," but questions remain on differentiation in the post immuno-oncology setting and the ability to combine and secure a spot in earlier lines, the analyst tells investors in a research note. JPMorgan believes Xencor needs greater clarity "on the pace of execution and truly needle-moving catalysts" for the shares to move higher. As such, it expects the shares to be range-bound.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for XNCR

Unlock Now

Valuation Metrics

The current forward P/E ratio for Xencor Inc (XNCR.O) is 68.03, compared to its 5-year average forward P/E of -5.51. For a more detailed relative valuation and DCF analysis to assess Xencor Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.51

Current PE

68.03

Overvalued PE

12.85

Undervalued PE

-23.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.19

Current EV/EBITDA

-3.99

Overvalued EV/EBITDA

12.22

Undervalued EV/EBITDA

-20.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

13.88

Current PS

6.35

Overvalued PS

19.97

Undervalued PS

7.78

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

of all the listed stocks pick one please

Intellectia · 111 candidates

Price: $5.00 - $75.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEWeek Price Change Pct: >= $5.00One Day Rise Prob: >= 65Monthly Average Dollar Volume: >= 1,500,000

Ticker

Name

Market Cap$

RYAM

Rayonier Advanced Materials Inc

685.47M

ADEA

Adeia Inc

2.26B

IMAX

Imax Corp

1.96B

IRON

Disc Medicine Inc

2.53B

FPI

Farmland Partners Inc

564.25M

SKT

Tanger Inc

4.31B

stock of the day for swing trade

Intellectia · 517 candidates

Price: $10.00 - $150.00Rsi Category: moderateRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20One Week Predict Return: >= 0.0%Monthly Average Dollar Volume: >= 1,500,000

Ticker

Name

Market Cap$

CLDX

Celldex Therapeutics Inc

2.05B

XNCR

Xencor Inc

855.50M

MEG

Montrose Environmental Group Inc

826.19M

TRI

Thomson Reuters Corp

44.22B

PHAT

Phathom Pharmaceuticals Inc

961.13M

CAVA

CAVA Group Inc

9.94B

Whales Holding XNCR

TCG Crossover Management, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Xencor Inc (XNCR) stock price today?

The current price of XNCR is 12.31 USD — it has decreased -1.05

What is Xencor Inc (XNCR)'s business?

What is the price predicton of XNCR Stock?

Wall Street analysts forecast XNCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XNCR is26.25 USD with a low forecast of 20.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Xencor Inc (XNCR)'s revenue for the last quarter?

Xencor Inc revenue for the last quarter amounts to 28.24M USD, decreased -59.67

What is Xencor Inc (XNCR)'s earnings per share (EPS) for the last quarter?

Xencor Inc. EPS for the last quarter amounts to -0.09 USD, decreased -87.67

How many employees does Xencor Inc (XNCR). have?

Xencor Inc (XNCR) has 260 emplpoyees as of April 08 2026.

What is Xencor Inc (XNCR) market cap?

Today XNCR has the market capitalization of 902.80M USD.

XNCR Overview

XNCR Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Related Community Screener

Whales Holding XNCR

Trading Trends

People Also Watch

Frequently Asked Questions

What is Xencor Inc (XNCR) stock price today?

What is Xencor Inc (XNCR)'s business?

What is the price predicton of XNCR Stock?

What is Xencor Inc (XNCR)'s revenue for the last quarter?

What is Xencor Inc (XNCR)'s earnings per share (EPS) for the last quarter?

How many employees does Xencor Inc (XNCR). have?

What is Xencor Inc (XNCR) market cap?